Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of romiplostim in
thrombocytopenic patients with low or Intermediate-1 risk MDS. In addition, the study will
evaluate the platelet response to romiplostim.